New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
09:09 EDTKOOLCesca Therapeutics, Cook Medical enter supply agreement for Phase 1b trial
Cesca Therapeutics announced today that they have entered a supply agreement with Cook Medical. Under the terms of the agreement, Cook Medical has been chosen as the supplier for select delivery device products for the Acute Myocardial Infarction Rapid Stem cell Therapy, or AMIRST, Phase 1b trial set to begin later this calendar year. The clinical trial is for targeted marketing approval in the United States, European Union Community and India.
News For KOOL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2015
09:10 EDTKOOLCesca Therapeutics secures $15M financing from institutional life sciences fund
Cesca Therapeutics announced the signing and initial closing of a definitive agreement on August 31 to raise $15M in senior secured convertible debentures and warrants from one institutional investor. The company intends to use the gross proceeds from the private placement for working capital in support of its ongoing clinical initiatives. The company received $5.5M in gross proceeds at the initial closing. At the second closing, the balance of $9.5M will be placed into a restricted control account and will be released to the company upon the achievement of agreed upon milestones, including approval from the California Institute for Regenerative Medicine of the company's application for matching funds in the form of a CIRM grant. The debentures bear no interest, may be convertible into shares of the company's common stock at a conversion price of $0.68 per share and are secured by all of the company's assets. In connection with the transaction, the company also issued Series A warrants to purchase up to 22,058,823 million shares of the common stock at $0.68 for a period of five and one-half years and Series B warrants to purchase up to 12,132,353 million shares of common stock at $0.68 for a period of eighteen months. The Series A and B warrants are subject to vesting based upon the amount of funds actually received by the company in the sale of the senior secured convertible debentures and are exercisable upon the earlier of the approval of the transaction by the company's stockholders and the 6 month anniversary of the issuance date.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use